Key Points
- Matrix Capital Management sold 6,922,870 shares of Aura Biosciences on May 7 at an average price of $5.64, a transaction worth about $39.0 million. The sale was disclosed in an SEC filing.
- Aura Biosciences recently reported quarterly EPS of ($0.50), missing analyst expectations of ($0.40). Analysts now expect the company to post -1.63 EPS for the full year.
- Despite mixed views, Wall Street’s consensus rating on AURA is Hold with an average price target of $21.50. HC Wainwright remains bullish, recently raising its target to $24 and keeping a buy rating.
Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) major shareholder Matrix Capital Management Comp sold 6,922,870 shares of the firm's stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $5.64, for a total value of $39,044,986.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Aura Biosciences Price Performance
AURA opened at $8.19 on Tuesday. The stock's 50 day simple moving average is $6.76 and its 200 day simple moving average is $6.08. Aura Biosciences, Inc. has a 1 year low of $4.34 and a 1 year high of $9.53. The firm has a market cap of $525.80 million, a price-to-earnings ratio of -4.58 and a beta of 0.37.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by ($0.10). As a group, sell-side analysts anticipate that Aura Biosciences, Inc. will post -1.63 EPS for the current year.
Analyst Ratings Changes
A number of brokerages recently issued reports on AURA. HC Wainwright boosted their price target on Aura Biosciences from $22.00 to $24.00 and gave the company a "buy" rating in a report on Wednesday, April 29th. Weiss Ratings restated a "sell (d-)" rating on shares of Aura Biosciences in a report on Friday, March 27th. Finally, Wall Street Zen upgraded Aura Biosciences from a "sell" rating to a "hold" rating in a report on Saturday, April 4th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Aura Biosciences has a consensus rating of "Hold" and an average target price of $21.50.
Read Our Latest Stock Analysis on AURA
Institutional Trading of Aura Biosciences
Hedge funds have recently made changes to their positions in the stock. Parallel Advisors LLC boosted its position in shares of Aura Biosciences by 130.4% in the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock worth $38,000 after purchasing an additional 3,206 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Aura Biosciences by 49.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock valued at $40,000 after purchasing an additional 2,104 shares during the last quarter. ProShare Advisors LLC purchased a new stake in Aura Biosciences during the 4th quarter valued at about $59,000. Water Island Capital LLC purchased a new stake in Aura Biosciences during the 3rd quarter valued at about $64,000. Finally, 49 Wealth Management LLC purchased a new stake in Aura Biosciences during the 3rd quarter valued at about $66,000. 96.75% of the stock is owned by institutional investors.
About Aura Biosciences
(
Get Free Report)
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
